Increase of serum CA19-9 level without an evident lesion on conventional imaging is insufficient for justification of 18FDG-PET examination

Hepato-Gastroenterology

Volumn 55, Issue 81, 2008, Pages 46-49

  Inoue, Kentaro ^a   Okada, Ken ^a   Taki, Yasuyuki ^a   Goto, Ryoi ^a   Kinomura, Shigeo ^a   Kaneta, Tomohiro ^b   Fukuda, Hiroshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

CA19 9; Fluorodeoxyglucose F18; Positron emission tomography; Screening; Tumor markers

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HISTORY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE;

ADULT; AGED; CA-19-9 ANTIGEN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 41549126336     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kole AC, Nieweg OE, Pruim J, Hoekstra HJ, Koops HS, Roodenburg JL, et al: Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998; 82:1160-1166.
2. Zimny M, Siggelkow W, Schroder W, Nowak B, Biemann S, Rath W, et al: 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol 2001; 83:310-315.
3. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al: Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995; 21:517-522.
4. Jadvar H, Fischman AJ: Evaluation of pancreatic carcinoma with FDG PET. Abdom Imaging 2001; 26:254-259.
5. Duffy MJ: CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998; 35(Pt 3):364-370.
6. Lamerz R: Role of tumour markers, cytogenetics. Ann Oncol 1999; 10(Suppl 4):145-149.
7. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24:2897-2902.
8. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW: Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19:182-186.
9. Satake K, Takeuchi T, Homma T, Ozaki H: CA19-9 as a screening and diagnostic tool in symptomatic patients: the Japanese experience. Pancreas 1994; 9:703-706.
10. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Phelps ME, et al: A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189.
11. Higashi T, Saga T, Nakamoto Y, Ishimori T, Fujimoto K, Doi R, et al: Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) - usefulness and limitations in "clinical reality". Ann Nucl Med 2003; 17:261-279.
12. Franke C, Klapdor R, Meyerhoff K, Schauman M: 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999; 19:2437-2442.
13. Ruf J, Lopez Hanninen E, Oettle H, Plotkin M, Pelzer U, Stroszczynski C, et al: Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005; 5:266-272.
14. Enomoto K, Fukunaga T, Okazumi S, Asano T, Kikuchi T, Yamamoto H, et al: [Can fluorodeoxyglucose-positron emission tomography evaluate the functional differentiation of hepatocellular carcinoma]. Kaku Igaku 1991; 28:1353-1356.
15. Trojan J, Schroeder O, Raedle J, Baum RP, Herrmann G, Jacobi V, et al: Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94:3314-3319.
16. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM: Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003; 44:1407-1412.
17. Yoshioka T, Yamaguchi K, Kubota K, Saginoya T, Yamazaki T, Ido T, et al: Evaluation of 18F-FDG PET in patients with a, metastatic, or recurrent gastric cancer. J Nucl Med 2003; 44:690-699.
18. Suzuki A, Kawano T, Takahashi N, Lee J, Nakagami Y, Miyagi E, et al: Value of 18F-FDG PET in the detection of peritoneal carcinomatosis. Eur J Nucl Med Mol Imaging 2004; 31:1413-1420.
19. Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K: Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Am J Gastroenterol 1985; 80:630-636.
20. Safi F, Beger HG, Bittner R, Buchler M, Krautzberger W: CA 19-9 and pancreatic adenocarcinoma. Cancer 1986; 57:779-783.
21. Mukae H, Hirota M, Kohno S, Komori K, Fukushima K, Hiratani K, et al: Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 148:744-751.
22. Matalliotakis I, Panidis D, Vlassis G, Neonaki M, Goumenou A, Koumantakis E: Unexpected increase of the CA 19-9 tumour marker in patients with endometriosis. Eur J Gynaecol Oncol 1998; 19:498-500.